Income Statement (TTM)
Monte Rosa Therapeutics, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|
| Revenue | 1 | 6 | 15 | 76 | 159 | 178 |
| Change (%) | 441.26 | 160.03 | 404.99 | 110.90 | 11.60 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 104 | 154 | 102 | 113 | 118 | 121 |
| Change (%) | 48.42 | -34.03 | 11.12 | 4.60 | 2.86 | |
| % of Revenue | 9,749.34 | 2,673.31 | 678.26 | 149.25 | 74.02 | 68.23 |
| Gross Operating Profit | -103 | -148 | -87 | -37 | 41 | 57 |
| Change (%) | 44.34 | -41.57 | -56.99 | -211.24 | 36.50 | |
| % of Revenue | -9,649.34 | -2,573.31 | -578.26 | -49.25 | 25.98 | 31.77 |
| SG&A | 41 | 43 | 42 | 44 | 44 | 42 |
| Change (%) | 3.45 | -0.87 | 3.51 | -0.72 | -4.51 | |
| % of Revenue | 3,884.40 | 742.39 | 283.03 | 58.01 | 27.31 | 23.37 |
| R&D | -52 | |||||
| Change (%) | ||||||
| % of Revenue | -894.79 | |||||
| OpEx | 145 | 145 | 144 | 157 | 162 | 163 |
| Change (%) | 0.08 | -0.84 | 8.88 | 3.11 | 0.87 | |
| % of Revenue | 13,633.74 | 2,520.91 | 961.30 | 207.26 | 101.33 | 91.60 |
| Operating Income | -144 | -139 | -129 | -81 | -2 | 15 |
| Change (%) | -3.18 | -7.49 | -37.11 | -97.38 | -802.63 | |
| % of Revenue | -13,533.74 | -2,420.91 | -861.30 | -107.26 | -1.33 | 8.40 |
| Interest Expense | ||||||
| Change (%) | ||||||
| % of Revenue | ||||||
| Net Income | -135 | -130 | -119 | -73 | 6 | 24 |
| Change (%) | -3.60 | -8.45 | -39.11 | -108.46 | 292.78 | |
| % of Revenue | -12,714.47 | -2,264.53 | -797.26 | -96.14 | 3.86 | 13.58 |
Source: Capital IQ
